Author Topic: New study by NIH claims Remdesivir reduces mortality and length of stay???  (Read 1292 times)

admin

  • Administrator
  • Hero Member
  • *****
  • Posts: 3090
After the giant long term WHO trial that came out at about the same time, that confirmed that Remdesivir does not significantly reduce mortality and in this trial even suggested it does not reduce hospital stay, the NIH/Fauci pulled a fresh new rabbit out of their hat. Based on the abject lie it begins with, perhaps it should be taken with a shaker of salt:

"Abstract
Background
Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious."

That is a filthy lie. https://www.covid-19forum.org/index.php?board=3.0

https://www.nejm.org/doi/full/10.1056/NEJMoa2007764

"Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days."

So the 10 day course of treatment must run about $6400. Such a deal!

A big fat lie like that after destroying the reputation of 65-year old proven-safe hydroxychloroquine, through a fraudulent study that was larded with panel members that had financial interests or other ties to Gilead Sciences, while HCQ continues to be up to 99-100% effective with a $20 treatment protocol in the early outpatient setting.
https://www.covid-19forum.org/index.php?topic=5.0

added 5-2-21:  "PulmCrit – Eleven reasons the NEJM paper on remdesivir reveals nothing"
https://www.covid-19forum.org/index.php?topic=217.0
« Last Edit: May 29, 2021, 01:16:28 PM by admin »
www.covidtreatmentoptions.com/
Over a million Americans died completely unnecessary, horrific, deaths from COVID-19. Do you have a plan in place to help your family dodge the average $73,300 COVID hospital bill, through prevention and $20 EARLY treatment? https://www.covidtreatment